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Background: Biofilm bacteria are relatively more resistant to antibiotics. The escalating trend of antibiotic resistance
higlights the need for evaluating alternative potential therapeutic agents with antibacterial properties. The use of
honey for treating microbial infections dates back to ancient times, though antimicrobial properties of Manuka
honey was discovered recently. The aim of this study was to demonstrate biofilm formation of specific Clostridium
difficile strains and evaluate susceptibility of the biofilm to Manuka honey.
Methods: Three C. difficile strains were used in the study including the ATCC 9689 strain, a ribotype 027 strain and
a ribotype 106 strain. Each test strain was grown in sterile microtitre plates and incubated at 37°C for 24 and
48 hours in an anaerobic cabinet to allow formation of adherent growth (biofilm) on the walls of the wells. The
effect of Manuka honey on the biofilms formed was investigated at varying concentrations of 1-50% (w/v) of
Manuka honey.
Results: The three C. difficile strains tested formed biofilms after 24 hours with the ribotype 027 strain producing
the most extensive growth. There was no significant difference (p > 0.05) found between the amount of biofilms
formed after 24 and 48 hours of incubation for each of the three C. difficile strains. A dose–response relationship
between concentration of Manuka honey and biofilm formation was observed for all the test strains, and the
optimum Manuka honey activity occurred at 40-50% (v/v).
Conclusion: Manuka honey has antibacterial properties capable of inhibiting in vitro biofilm formed by C. difficile.
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Biofilms are complex structures of polysaccharide matrix
excreted by bacteria in a form of slimy, glue-like sub-
stance that adhere to material surfaces especially, when
exposed to some amount of water [1]. Within the last
decade, many studies have been done on biofilms which
have established their association with infections and
contaminations [1]. The conventional methods of killing
bacteria by using antibiotics and disinfection are often
unsuccessful with biofilm forming bacteria [1]. Thus bio-
film forming bacteria may pose a relatively greater threat
to public health. For instance, it is reported that patients
suffering from biofilm associated infections tend to stay
longer in hospital than expected [2,3]. Worldwide, it is
estimated that biofilms are associated with 65 percent of* Correspondence: hammondes@yahoo.com
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article, unless otherwise stated.nosocomial infections and contribute to high death rate
and 2-14% of all surgical wounds complications [2]. Bio-
film formation by bacteria also has serious economic im-
plications. It is reported that a microorganism associated
with biofilm formation is reported to cost some nations
billions of dollars yearly in medical infections, equip-
ment damage and product contamination [4].
Some bacterial organisms known to form biofilms in-
clude Pseudomonas aeruginosa, Staphylococcus aureus,
Listeria monocytogenes and Clostridium difficile [5,6].
Biofilm formation by C. difficile was first reported in
2012 and has since then been demonstrated with a few
strains of the organism [7-10]. Evidence from some stud-
ies indicate that amount of biofilm formed by C. difficile
varies from strain to strain [4,5]. Mutagenesis studies
have identified several surface proteins such as SlecC,
Cwp84 and LuxS that are required for biofilm formation
of C. difficile [8,10]. There is also evidence that some
level of sporulation occurs in C. difficile biofilm [11,12].tral Ltd. This is an Open Access article distributed under the terms of the
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dates back to ancient times, though antimicrobial prop-
erties of Manuka honey was discovered recently. The
antibacterial effect of Manuka honey against bacterial
biofilms has been demonstrated for several organisms
such as Streptococcus pyogenes [13], Pseudomonas aeru-
ginosa [14], Enterococcus faecalis [15] and Streptococcus
mutans [16]. Bactericidal effects have been found in
both planktonic cultures and biofilm, although higher
concentrations were required to inhibit biofilms [17]. In
a biofilm study, Maddocks et al. [17] reported that sub-
lethal concentrations of Manuka honey disrupted the
binding of S. pyogenes to the human fibronectin but did
not prevent binding to fibrinogen. Manuka honey thus
appears to be a promising antibacterial agent in this era
of diminishing antimicrobial agents. However, further
studies on its antibacterial properties are required espe-
cially, with highly resistant pathogens such as C. difficile.
C. difficile, the causative agent of severe inflammation
of the bowel (pseudomembranous colitis), has become
the most significant nosocomial antibiotic-associated
diarrhoea reported worldwide [18,19]. The Centers for
Disease Control and Prevention (CDC) estimate that
nearly 250,000 serious C. difficile infections (CDI) occur
in the US annually, at a cost of at least one billion dol-
lars, resulting in 14,000 deaths (CDC, 2013) [20]. This
high public health burden associated with C. difficile is
partly due to the trend of increasing resistance of the or-
ganism to several essential antibiotics, a problem which
highlights the need for alternative treatment methods of
C. difficile infections. In a previous study, we demon-
strated the susceptibility of C. difficile to Manuka honey
(Leptospermum scoparium) [21]. The findings of the
study showed that Manuka honey exhibits a bactericidal
activity against C. difficile with minimum inhibitory and
bactericidal concentrations of 6.25% (v/v) [21]. However,
it is unknown if biofilm formed by C. difficle is also
susceptible to Manuka honey. Biofilm formation by C.
difficile in itself has been recently reported, and it is
important to confirm this with various C. difficile strains.
The aim of this study was to demonstrate biofilm forma-
tion of specific strains of C. difficile and the antibacterial
effect of Manuka honey on the C. difficile biofilm.
Methods
Clostridium difficile strains
Three C. difficile strains were used for the experiments
in this study, and they included the ATCC 9689 strain, a
ribotype 027 strain and a ribotype 106 strain. These
strains were selected for the study due to their epidemio-
logical or clinical significance. The C. difficile strains were
obtained from University of Wales Hospital and were
maintained in Robertson’s Cook meat medium (Oxoid,
Cambridge, UK) at the Department of Microbiology,University of Wales Institute Cardiff where the study was
carried out. Prior to using the C. difficile strains in the ex-
perimental work, they were purified on blood agar plates.
Manuka honey
Woundcare™ 18+ Active Manuka honey (potency equiva-
lent of greater than 18% (w/v) phenol) with non-peroxide
antibacterial activity from Comvita UK was used in this
study.
Microtitre plate assay for the assessment of biofilm
formation in C. difficile strains
The experiments performed to determine the capability
of the C. difficile strains to form biofilms were based on
the previously described methods [4]. The three C. difficile
test strains were cultured overnight in Reinforced Clos-
tridial Medium (RCM) broth at 37°C for 24 hours. For
each strain, a dilution of 1:100 inoculum was made in a
sterile broth bottle by pipetting 1 ml of each strain into
99 ml of RCM broth and vortexing to achieve a good mix-
ture. An aliquot of 200 μl of each diluted inoculum was
dispensed into a 96-well Nunc flat bottom microtitre
plate. The plates and contents were incubated at 37°C for
24 and 48 hours in an anaerobic cabinet to allow for for-
mation of biofilms on the walls of the wells. For each ex-
periment, wells of RCM broth without C. difficile strains
were used as negative control. At the end of the 24 and
48 hours of incubation, the plates were removed from the
anaerobic cabinet and the cultures were carefully removed
by using a Pasteur pipette. Subsequently, 200 μl of 2.5%
glutaraldehyde solution was pipetted into each of the
drained wells, and allowed to stand for 5 minutes to allow
fixation. The glutaraldehyde solution was then removed
and the empty wells were washed by dispensing 200 μl of
phosphate buffered saline (PBS) (Oxoid, Cambridge, UK)
in them. The PBS was discarded and the wells were
stained with 200 μl of 0.25% (w/v) aqueous crystal violet
for 5 minutes. After this time, the wells were washed with
PBS eight times and allowed to air dry. The quantity of
biofilm formed was analyzed by adding 200 μl solvent (1:1
ethanol and acetone solution) to each well to dissolve dye
from adherent cells (biofilm). Absorbance was measured
within 5 minutes of adding the solvent at 570 nm using a
Dynex plate reader. The microtitre plate biofilm assay was
performed three times on separate occasions for all test C.
difficile strains.
Determination of the effect of various honey
concentrations on C. difficile biofilms
The three C. difficile test strains were cultured overnight
in an RCM broth at 37°C for 24 hours. For each strain,
an aliquot of 200 μl of each diluted inoculum (as de-
scribed in Section 3.3) was dispensed into each well of a
96-microtitre plate, starting from the first column (Column
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tive control). The last column (Column 12) contained
RCM only (no inoculum) and was used as a negative con-
trol. Outer rows and columns were unused, except for col-
umn 12 to avoid edge effects. The plates were incubated
at 37°C for 24 hours in an anaerobic cabinet to allow for
the formation of biofilms on the walls of the wells. After
incubation, a sterile Pasteur pipette was used to carefully
remove the liquid phase containing any planktonic growth
from each well into a discard jar, leaving adherent biofilm
attached to the well walls. However the positive control
was re-filled with 200 μl RCM to keep the biofilm alive.
With the exception the negative control wells, each well
was re-filled with 200 μl of Manuka honey solutions and
incubated at 37°C for 24 hours in an anaerobic cabinet.
Different concentrations of Manuka honey (0, 1, 2, 4, 8,
10, 20, 30, 40, 50% (w/v)) were included in the experimen-
tal setup and were prepared by dilutions with RCM.
After incubation, the liquid phase in each well (con-
taining any overnight planktonic growth together with
the honey solutions) was discarded into the discard jar
using a sterile Pasteur pipette. The adherent growth was
fixed with 200 μl of 2.5% glutaraldehyde for 5 minutes.
The fixative was removed into a toxic waste bottle and
the wells washed twice with PBS. All the wells were
stained with 200 μl of 0.25% crystal violet for 5 minutes.
The stain was then removed and the wells washed 8
times with PBS. It was ensured that any remaining liquid
was drained from the plates by inverting them vigorously
onto paper hand towels. At this point, biofilms were vis-
ible as purple rings formed on the side of each well. The
quantity of biofilms formed were analysed by adding
200 μl solvent (1:1 ethanol and acetone solution) to each
well to dissolve dye associated cells. The reading was
taken (within 5 minutes of adding the solvent) at
570 nm in a Dynex plate reader. The microtitre plateFigure 1 Formation of adherent growth (biofilm) by C. difficile strainsbiofilm assay was performed three times on separate oc-
casions for all C. difficile test strains.
Statistical analysis
The experimental data was entered into Microsoft Excel®
2010 and analyzed. Mean biofilm biomass was calculated
for each C. difficile strain at 24 and 48 hours. The Stu-
dent's t-test was used to test for any significant differ-
ence between biofilms formation as function of the
hours for the different strains. A p- value less than or
equal to 0.05 was considered significant.
Results and discussion
In this study we investigated biofilm formation of C.
difficile and the susceptibility to Manuka honey. Figure 1
shows that all the three C. difficile strains formed biofilms
and there was no significant difference (p = 0.3901) be-
tween biofilm formation in 24 hours and biofilm forma-
tion in 48 hours.
Bacterial biofilm formation occurs through an interest-
ing mechanism which first involves bacterial attachment
to a material surface. This initial attachment of the bacter-
ial organism is influenced mainly by combination of envir-
onmental factors (such as nutrient levels, temperature, pH
and duration of attachment) and genetic factors [1]. Im-
mediately the cells are attached to suitable surfaces, they
begin to multiply and grow to form a thin layer (mono-
layer) towards where conditions are favourable on
material surfaces. At this stage, the cells undergo a devel-
opmental change which lead to the production of a com-
plex structure referred to as exopolysaccharide glycocalyx
polymers matrix and is one of the hallmarks of a matured
biofilm [22-24].
The ability of C. difficile to form biofilms as observed
in this study concurs with studies carried out by several
other investigators [7-10]. As shown in Figure 1, amongafter 24 and 48 hours incubation.
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showed the highest potential for biofilm formation. Bio-
film formation has been linked with virulence of several
bacterial pathogens including C. difficile [8,13]. C. difficile
of ribotype 027 is known to be a hypervirulent strain and
the commonest cause of C. difficile associated outbreaks
[25]. Data from our study appear to indicate that the high
virulence and epidemiological significance of C. difficile
ribotype 027 strains may be related to its relatively greater
ability to form biofilms compared to other C. difficile
strains such as ribotype 106 strains. In their study of C.
difficile biofilm, Dapa et al. [8] also observed that the hy-
pervirulent strain (ribotype 027) produced more biofilm
than a less virulent C. difficile strain. Currently, very little
is known about the actual role of biofilm in the pathogen-
icity and pathogenesis of C. difficile, and further studies
are required to elucidate this.
The extent of Manuka honey inhibiting the established
biofilm was determined by comparing the amount of
biofilm formed in the wells with and without Manuka
honey. This experiment showed that generally, there was
a dose–response relationship between the amount of
biofilm depleted and concentration of Manuka honey
(Figure 2). Concentrations of Manuka honey below 20%
(w/v) appeared to have no or little effect on the estab-
lished biofilm for each of the three C. difficle strains.
However, concentrations between 20 and 50% (w/v)
Manuka honey resulted in decreasing amount of biofilm
formed by all test strains after 24 hours. Although MIC
and MBC of Manuka honey against suspensions of the
C. difficile strains used in this study were 6.25% (v/v)
[21], much higher concentrations of 30-50% (w/v) of
Manuka honey were required to deplete biofilms formed
by the C. difficile strains.
This may be due to the ability of the sessile bacteria
(biofilm formed by C. difficile) to secrete proteins andFigure 2 The effect of varying concentrations of Manuka honey on bpolymeric sugars which serve as a protection to enhance
quorum development for survival [1]. Similar results
were reported by Okhiria et al. [26]. Fux et al. [27]
showed that biofilms are strongly resistant to biocides,
drying and most environmental stresses. Ashby et al.
[28] and Costerton et al. [29] reported that the ability of
biofilm to resist antibiotic effect could be due to the
slow growth rate of biofilm, since the effect of bacteri-
cides on biofilm usually declines with lower growth rate.
From this study, it may be inferred that the most suit-
able Manuka honey concentrations to inhibit C. difficile
biofilm significantly were 40 and 50% (w/v). Similarly,
Okhiria et al. [26] reported that Pseudomonas biofilm
exposed to 40% (w/v) Manuka honey concentration
showed a significant inhibition, but 20% (w/v) Manuka
honey did not show any significant inhibition. From
Figure 2, it can be observed that Manuka honey could
not exhibit 100% depletion of biofilm formed by the C.
difficile strains. Studies by Alandejani et al. [30] also re-
ported that the effectiveness of Manuka honey against
biofilms formed by S. aureus and P. aeruginosa were less
than 100%. Nevertheless, based on this study and others,
it is important to note that Manuka honey has an appre-
ciable antibacterial activity against biofilm formed by
bacterial organisms [31]. While in this study we demon-
strated the ability of Manuka honey to inhibit biofilm
formation of C. difficile, Maddock et al. [17] demon-
strated the ability of Manuka honey to disrupt pre-
formed biofilms of Streptococcus pyogenes. Recently,
Ansari et al. [31] also reported that Jujube honey can
disrupt pre-formed biofilms of Candida albicans. Anti-
microbial effect of Manuka honey is due to a property
referred to as Unique Manuka Factor that is absent in
other types of honey [32]. Various studies have revealed
that the active ingredient in Manuka honey is Methyl-
glyoxal [33,34], and this compound is known to haveiofilm of C. difficile strains.
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lin [35].
We previously demonstrated susceptibility of C. diffi-
cile to Manuka honey, and in this study, have also shown
that biofilm formed of the organism is similarly suscep-
tible to Manuka honey. Overall these findings have im-
portant applications in the treatment of C. difficile
infections given the escalating trend of the organism to
several essential antibiotics. In the light of the findings
of the current study, it is also important for further stud-
ies to determine the rate and concentrations at which
Manuka honey inhibits biofilms of C. difficile in vivo.
Additionally, it would useful to investigate the effect of
Manuka honey on spores of C. difficile.
Conclusions
In this study, we have demonstrated biofilm formation
of specific C. difficile strains including ATCC 9689, ribo-
type 027 and ribotype 106. We have also shown that
Manuka honey exhibits antibacterial activity against C.
difficile biofilm with the optimum activity occurring at
40-50% (w/v). The bactericidal action of Manuka honey
may be exploited practically by incorporating a solution
of 40-50% (w/v) Manuka honey in topical and hand-
washing formulations in care homes and hospitals or
places where C. difficile populations are likely to be high.
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